NCT02387788View on ClinicalTrials.gov

Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions

Retinal Vein Occlusion

Interventions

DRUG

AKB-9778

Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.

Trial Locations (1)

21287

Wilmer Eye Institute, Baltimore